ESPE Abstracts

Background: Vosoritide is a biological analogue of C-type natriuretic peptide, which promotes endochondral ossification by suppressing FGFR3 downstream signaling in achondroplasia (ACH). It is the first drug targeting the pathophysiology of ACH and was launched in Japan in August 2022, for the first time in the world without a minimum age limit. There have been no reports on the efficacy and safety of vosoritide other than clinical trials.<p class="abstext...